SYHA1813

DRUG3 trials

Sponsors

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Conditions

High Grade MeningiomaRecurrent or Progressive High Grade MeningiomaUnresectable Locally Advanced or Metastatic Solid Tumors

Phase 1

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Not yet recruitingNCT06682611

Shanghai Runshi Pharmaceutical Technology Co., LtdUnresectable Locally Advanced or Metastatic Solid Tumors

Start: 2024-11-13End: 2027-11-13Target: 380Updated: 2024-11-12

Phase 2

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

Not yet recruitingNCT06739213

Shanghai Runshi Pharmaceutical Technology Co., LtdRecurrent or Progressive High Grade Meningioma

Start: 2025-01-31End: 2028-01-13Target: 56Updated: 2024-12-18

Phase 3

A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas

Not yet recruitingNCT07613450

Shanghai Runshi Pharmaceutical Technology Co., LtdHigh Grade Meningioma

Start: 2026-05-20End: 2029-10-15Target: 136Updated: 2026-05-29